Energised by a debt recast, Chennai-based Orchid Chemicals and Pharmaceuticals is looking at the West to return to profitability.
Hit by working capital constraints and high interest costs, the company posted a loss of Rs.530.23 crore in the 18 months ended September 2013, compared with a profit of Rs.103.11 crore in fiscal 2011-12.
Non-antibiotic formulations constitute a $16-billion market in the US and the company has also filed for licences to market 30 generic drugs in the European Union. “The growth in the non-antibiotic formulations will come through product launches over the next two-three years in these markets,” K Raghavendra Rao, Chairman and Managing Director, told shareholders at the company’s AGM here. A US subsidiary for marketing its drugs and a research unit, Bexel Pharmaceuticals Inc, will help widen Orchid’s presence in the US.
Patients Embrace Flexibility with 37% of Online Doctor Consultations now happening even After 6 PM,…
Launches Advanced Pathology Laboratory Offering Over 2500+ Tests in collaboration with Parashar Pathology Clinic in…
By Dr. Brajmohan Singh, Cardiothoracic and Vascular Surgeon, HCG Hospitals, Bhavnagar Cardiovascular health is vital…
By Ms. Soumita Biswas, Chief Clinical Nutritionist, Aster RV Hospital Every year, International Mind-Body Wellness…
By Dr Bhavisha Ghughare, Consultant –Surgical Oncology and Breast Oncoplastic Surgeon, HCG Cancer Center, Borivali,…
By Dr. Srinivasa Murthy C L, Lead Paediatrics, Consultant – Paediatrics and Neonatology, Aster Women…